The current gold standard of care for patients with HER2-positive (HER2+) breast cancer is trastuzumab in combination with pertuzumab, a humanized monoclonal antibody leading to inhibition of the dimerization of HER2 [2, 3]. Here, ERBB2 is linked to breast carcinoma.